Leuprolide for Alzheimer's Disease (LUCINDA Trial)

"Affirmative, according to clinicaltrials.gov this medical trial remains open for recruitment after its initial posting on November 27th 2020 and most recent update occurring August 1st 2022. Currently the study is searching for 180 patients across 4 separate facilities."

"Currently, 64 experiments assessing Eligard 22.5Mg Suspension for Injection are in progress with 24 of them classified as Phase 3 trials. Besides the numerous sites located in Duarte, California, a total of 5355 other research centres have taken up studies on this medication across the globe."

"This clinical trial seeks 180 senior citizens aged between 65 and 120 with a confirmed diagnosis of Alzheimer's disease. With regards to eligibility, the individuals must be post-menopausal females, present with a Hachinski score below 5 that indicates dementia is not of vascular origin, abstain from consuming memantine (Namenda), have a MOCA score above 11 or Blind MOCA higher than 8 at screening visit, reside at home or another facility other than nursing homes accompanied by an individual who visits them for 10 hours per week minimum and can sign consent forms as well as accompany patients during clinic visits."

"At present, 4 medical centres are administering this trial; these include facilities in Boca Raton, Madison and New york City with an additional four elsewhere. To reduce travel demands for prospective participants, it is best to select the research site closest to you."

"Eligard 22.5Mg Suspension for Injection is the standard of care when it comes to treating advanced prostate cancer, though there are other medical issues where this injection can be beneficial such as anemia and central precocious puberty."

"The eligibility requirements for this trial necessitate that participants are between 65 and 120 years old. According to the clinical trials database, 47 studies exist for younger patients while 992 trials cater to seniors."

"Our company's appraisal of Eligard 22.5Mg Suspension for Injection is a 2, as the medication has already been through Phase 2 trials showing some evidence that it is safe but none yet demonstrating its efficacy."

"The details listed on clinicaltrials.gov suggest this experiment is actively recruiting volunteers; it was initially posted November 27th 2020 and its information has been revised most recently on August 1st 2022."